Galectin Therapeutics (GALT) Interest Expenses (2018 - 2026)

Galectin Therapeutics' Interest Expenses history runs 16 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 13.99% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $12.9 million (up 28.42% YoY), while the FY2025 annual figure was $95.7 million, up 5.89% from the prior year.
• Interest Expenses for Q1 2026 stood at $2.0 million, down from $7.3 million in the prior quarter.
• The five-year high for Interest Expenses was $7.3 million in Q4 2025, with the low at $55000.0 in Q4 2023.
• The 5-year median for Interest Expenses is $1.1 million (2024), against an average of $1.6 million.
• The sharpest annual moves came in 2023 and 2024: Interest Expenses slumped 93.77% in 2023, then jumped 9972.73% in 2024.
• Galectin Therapeutics' Interest Expenses stood at $883000.0 in 2022, then plunged by 93.77% to $55000.0 in 2023, then surged by 9972.73% to $5.5 million in 2024, then jumped by 31.19% to $7.3 million in 2025, then sank by 72.65% to $2.0 million in 2026.
• Business Quant data shows GALT's Interest Expenses at $2.0 million in Q1 2026, $7.3 million in Q4 2025, and $1.8 million in Q3 2025.